TrialSignal transduction and targeted therapy2024

First-line penpulimab (an anti-PD1 antibody) and anlotinib (an angiogenesis inhibitor) with nab-paclitaxel/gemcitabine (PAAG) in metastatic pancreatic cancer: a prospective, multicentre, biomolecular exploratory, phase II trial.

Huizi Sha et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.